Merck Animal Health Receives the EC’s Approval of BRAVECTO TriUNO for Use in Dogs
Shots:
- The EC has approved BRAVECTO TriUNO for dogs targeting internal and external parasites & will be available through veterinarians. It is also approved in Peru, Guatemala, Nicaragua & Costa Rica
- BRAVECTO TriUNO is indicated for targeting tick & flea infestations with persistent activity for 1mos., treating infections due to gastrointestinal nematodes (roundworms & hookworms) as well as preventing heartworm disease & angiostrongylosis in dogs
- BRAVECTO TriUNO is a flavored chewable tablet for dogs and puppies (8+ wks., ≥1.27 kg), consisting of 3 anti-parasitic agents namely, fluralaner (targets ticks and fleas), moxidectin (targets external systemic & internal parasites) & pyrantel (targets internal parasites)
Ref: Merck Animal | Image: Merck Animal
Related News:- Merck Animal Health Reports the EMA’s Approval of an Expanded Indication for SC Administration of Bovilis Rotavec Corona
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
